文献速递妇科产科

卵巢癌治疗与总生存的种族差异:指南依从性并非独立关联因素

Disparities in ovarian cancer treatment and overall survival according to race: An update.
PubMed 文献 · Gynecol Oncol · 2021-07-12

基于国家癌症数据库2012–2016年29,948例上皮性卵巢癌患者的回顾性研究,比较白人(93%)与黑人(7%)患者。黑人患者更常为IV期(OR 1.45)且在综合或学术机构治疗,但指南依从性不预测黑人种族(OR 1.0021,P=0.97)。白人总生存61.1个月,黑人49.3个月(P<0.0001),指南依从与非依从亚组中黑人中位生存均更短。

要点

  • 指南依从性并非黑人种族的独立预测因素(OR 1.0021,P=0.97)。
  • 黑人患者总生存更短(49.3 vs 61.1个月,P<0.0001)。
  • 需关注社会经济、环境及系统因素对生存差异的影响。

核心结论

  • 黑人患者与非NCCN指南导向治疗患者生存更差,但指南依从性并非独立关联黑人种族。
  • 生存差异可能由其他社会经济、环境及系统因素驱动。

研究设计与样本

  • 回顾性研究,来自国家癌症数据库2012至2016年诊断为上皮性卵巢癌且自我认同为白人或黑人的女性记录。
  • 共29,948例符合条件患者,白人27,744例(93%),黑人2,204例(7%)。
  • 暴露为对NCCN治疗指南的依从或不依从,结局为疾病特征差异和总生存月数。

主要发现

  • IV期疾病与黑人种族相关(OR 1.45,95%CI 1.23-1.70;P<0.001)。
  • 在综合机构治疗与黑人种族相关(OR 1.58,95%CI 1.16-2.15;P=0.0039)。
  • 在学术机构治疗与黑人种族相关(OR 2.30,95%CI 1.70-3.12;P<0.001)。
  • 指南依从性不预测黑人种族(依从OR 1.0021,95%CI 0.89-1.13;P=0.97)。
  • 白人依从治疗中位生存63.4个月,黑人为51.4个月(P=0.0001);白人非依从中位生存60.5个月,黑人为47.2个月(P<0.0001);白人总中位生存61.1个月,黑人为49.3个月(P<0.0001)。

关键数值与推荐

  • 指南依从性定义为对NCCN治疗指南的依从或不依从。
  • 黑人种族与IV期疾病OR 1.45(95%CI 1.23-1.70;P<0.001)、综合机构治疗OR 1.58(95%CI 1.16-2.15;P=0.0039)、学术机构治疗OR 2.30(95%CI 1.70-3.12;P<0.001)相关。
  • 指南依从与黑人种族OR 1.0021(95%CI 0.89-1.13;P=0.97)。
  • 白人依从治疗中位生存63.4个月 vs 黑人51.4个月(P=0.0001);非依从60.5 vs 47.2个月(P<0.0001);总中位生存61.1 vs 49.3个月(P<0.0001)。

临床怎么用

  • 临床应关注黑人卵巢癌患者更晚分期及治疗机构类型差异。
  • 不能仅以指南依从性解释生存差异,需评估社会经济、环境及系统因素。
  • 改善黑人患者生存需针对多层面因素干预,而非仅提高指南依从。

局限性

  • 回顾性数据库研究,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether guideline non-adherence is associated with Black race. METHODS: A retrospective review of National Cancer Database records of women diagnosed with epithelial ovarian cancer from 2012 to 2016 who identified as "White" or "Black" was performed. Exposure was adherence or non-adherence to National Comprehensive Cancer Network guidelines for treatment. Outcomes were differences in disease characteristics and overall survival in months. RESULTS: Of the 29,948 eligible patients, 93% (n = 27,744) were White and 7% (n = 2204) were Black. Having stage IV disease (OR 1.45, 95% CI 1.23-1.70; P < 0.001) and treatment in a comprehensive (OR 1.58, 95% CI 1.16-2.15; P = 0.0039) or academic (OR 2.30, 95% CI 1.70-3.12; P < 0.001) treatment facility were associated with Black race. Adherence to guidelines did not predict Black race (OR for adherence 1.0021, 95% CI 0.89-1.13; P = 0.97). Median survival for White patients with adherent care was 63.4 months and 51.4 months for Black patients (P = 0.0001). Median survival for White patients with non-adherent care was 60.5 months and 47.2 months for Black patients (P < 0.0001). Median overall survival was 61.1 months in White patients and 49.3 months in Black patients (P < 0.0001). CONCLUSIONS: Our data suggest that while Black patients and patients who receive non-NCCN guideline directed care have worse survival outcomes, guideline adherence is not independently associated with Black race. We must consider other socioeconomic, environmental and system factors that are contributing to the survival discrepancy in Black patients with ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Huffman DL, Jayakrishnan TT, Shankar K, et al. Disparities in ovarian cancer treatment and overall survival according to race: An update. Gynecol Oncol. 2021. PMID: 34261593. doi:10.1016/j.ygyno.2021.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。